MX2024007727A - Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona en el tratamiento de distrofias musculares congenitas. - Google Patents

Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona en el tratamiento de distrofias musculares congenitas.

Info

Publication number
MX2024007727A
MX2024007727A MX2024007727A MX2024007727A MX2024007727A MX 2024007727 A MX2024007727 A MX 2024007727A MX 2024007727 A MX2024007727 A MX 2024007727A MX 2024007727 A MX2024007727 A MX 2024007727A MX 2024007727 A MX2024007727 A MX 2024007727A
Authority
MX
Mexico
Prior art keywords
phthalazinedione
dihydro
amino
treatment
muscular dystrophies
Prior art date
Application number
MX2024007727A
Other languages
English (en)
Inventor
Wolfgang Brysch
Wegerer Jörg Von
Sara Schumann
Felix Brembeck
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of MX2024007727A publication Critical patent/MX2024007727A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de 5-amino-2,3-dihidro-1,4 -ftalazinadiona o una de sus sales farmacéuticamente aceptables en el tratamiento de distrofias musculares congénitas, especialmente distrofia muscular de Duchenne o distrofia muscular de Becker. La invención se refiere en particular al uso de la sal sódica de 5-amino-2,3-dihidro-1,4-ftalazinadiona para dichos fines. También se divulga una combinación farmacéutica de 5-amino-2,3-dihidro-1,4-ftalazinadiona o una de sus sales farmacéuticamente aceptables y un glucocorticoide para su uso en estas indicaciones. Se divulgan composiciones farmacéuticas, técnicas de formulación ventajosas y un método de tratamiento.
MX2024007727A 2022-01-07 2023-01-05 Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona en el tratamiento de distrofias musculares congenitas. MX2024007727A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22000008 2022-01-07
PCT/EP2023/000002 WO2023131579A1 (en) 2022-01-07 2023-01-05 Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies

Publications (1)

Publication Number Publication Date
MX2024007727A true MX2024007727A (es) 2024-07-01

Family

ID=79287836

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007727A MX2024007727A (es) 2022-01-07 2023-01-05 Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona en el tratamiento de distrofias musculares congenitas.

Country Status (12)

Country Link
US (1) US20250064801A1 (es)
EP (1) EP4460309A1 (es)
JP (1) JP2025503615A (es)
KR (1) KR20240132308A (es)
CN (1) CN118785909A (es)
AU (1) AU2023204891A1 (es)
CA (1) CA3240892A1 (es)
CL (1) CL2024001968A1 (es)
IL (1) IL313638A (es)
MX (1) MX2024007727A (es)
WO (1) WO2023131579A1 (es)
ZA (1) ZA202405280B (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953799B1 (en) * 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
WO2016096143A1 (de) * 2014-12-18 2016-06-23 Metriopharm Ag Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
EP3416951B1 (en) * 2016-02-16 2020-04-08 MetrioPharm AG Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
EP3248602A1 (en) * 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
US11918570B2 (en) * 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
EP4164651B1 (en) * 2020-06-10 2025-10-15 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for use in the treatment of coronaviral infections
PH12022553236A1 (en) * 2020-07-09 2024-02-12 Metriopharm Ag Glucocorticoid-sparing agent

Also Published As

Publication number Publication date
KR20240132308A (ko) 2024-09-03
US20250064801A1 (en) 2025-02-27
AU2023204891A1 (en) 2024-08-08
EP4460309A1 (en) 2024-11-13
CA3240892A1 (en) 2023-07-13
CL2024001968A1 (es) 2024-11-22
IL313638A (en) 2024-08-01
JP2025503615A (ja) 2025-02-04
ZA202405280B (en) 2025-10-29
WO2023131579A1 (en) 2023-07-13
CN118785909A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
BR112022007481A2 (pt) Lipídios ionizáveis e composições de nanopartículas dos mesmos
MX2025003420A (es) Compuesto de anillo fusionado con pirimidina, y su método de preparación y uso
BRPI0409227A (pt) composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
ECSP078002A (es) Formulaciones farmaceuticas de inhibidores de hdac
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
CL2017001983A1 (es) Composiciones farmacéuticas para terapia combinada.
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
NO20082269L (no) Nye piperaziner som antimalariamidler
DOP2003000678A (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
BR112022025134A2 (pt) 5-amino-2,3-dihidro-1,4-ftalazinadiona, composição, combinação, e, método de tratamento de uma infecção coronaviral
EP4313010A1 (en) Compounds for use in the treatment and prevention of covid- 19
HUP9700005A2 (hu) 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények
CY1116274T1 (el) Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας
JP5037121B2 (ja) 局所的適用のための爪再構成組成物
CL2024001968A1 (es) Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona en el tratamiento de distrofias musculares congénitas
Thaler et al. Differential effects of homocysteine and beta aminopropionitrile on preosteoblastic MC3T3-E1 cells
MX2024008371A (es) Compuestos organicos deuterados y usos de los mismos
US9642897B2 (en) Treatment of bone diseases
BR112023003506A2 (pt) Antagonista do receptor edg-2 cristalino e métodos de preparação
BR112022004032A2 (pt) Composições probióticas mixotróficas e usos das mesmas no tratamento de distensão abdominal
IL315130A (en) Compounds for use in the treatment of dystrophinopathies
CA3241898A1 (en) Nlrp3 oligonucleotide for use in preventing and/or treating an inflammatory disease
ZA202406961B (en) Combination of 5-amino-2,3-dihydro-1,4-phthalazinedione and a fumaric acid ester
EA201992149A1 (ru) Комбинация активных ингредиентов, содержащие ее композиции и их применение в лечении саркопении